Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure
NCT05236673 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 610
Last updated 2025-05-16
Summary
The primary objective of this study is to monitor the safety profile of Jardiance® in Korean patient with chronic heart failure (New York Heart Association (NYHA) class II-IV) in a routine clinical setting.
Conditions
Interventions
- DRUG
-
JARDIANCE® film-coated tablets 10mg
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-28
- Primary Completion
- 2025-04-30
- Completion
- 2025-04-30
Countries
- South Korea
Study Locations
More Related Trials
-
The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction
NCT06350487 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction
NCT05584319 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
NCT05556044 ·Status: RECRUITING ·Phase: PHASE3
-
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
NCT07038356 ·Status: RECRUITING ·Phase: PHASE3
-
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
NCT05879276 ·Status: RECRUITING ·Phase: PHASE3
-
Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure
NCT05949801 ·Status: COMPLETED ·Phase: PHASE3
-
Use of SGLT2i in noHCM With HFpEF
NCT06401343 ·Status: RECRUITING ·Phase: PHASE4
-
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
NCT03271879 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD
NCT05359263 ·Status: RECRUITING ·Phase: PHASE2
-
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
NCT03292653 ·Status: TERMINATED ·Phase: PHASE2
-
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
NCT06111768 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Empagliflozin in Hypertrophic Cardiomyopathy
NCT05182658 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
NCT00159614 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
NCT02226120 ·Status: COMPLETED ·Phase: PHASE3
-
Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
NCT03030222 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Ponsegromab in People With Heart Failure
NCT05492500 ·Status: TERMINATED ·Phase: PHASE2
-
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
NCT05953831 ·Status: WITHDRAWN ·Phase: PHASE2
-
ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy
NCT06580717 ·Status: RECRUITING ·Phase: PHASE4
-
A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure
NCT07218627 ·Status: RECRUITING ·Phase: PHASE1
-
EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
NCT02816736 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction
NCT07269717 ·Status: RECRUITING ·Phase: PHASE2
-
Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart Failure
NCT05770167 ·Status: UNKNOWN
-
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
NCT03030235 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
NCT00259038 ·Status: COMPLETED ·Phase: PHASE2
-
The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure
NCT05084235 ·Status: COMPLETED ·Phase: PHASE2